NEW YORK, May 6, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zenas BioPharma, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons who purchased or otherwise acquired Zenas BioPharma securities pursuant and/or traceable to the registration statement a ...

SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons who purchased or otherwise acquired Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Zenas BioPharma's September 2024 initial public offering. Zenas BioPharma purports to be a “clinical stage global biopharmaceutical company committed to being a leader in the development an ...

WASHINGTON, May 05, 2025 (GLOBE NEWSWIRE) -- Cohen Milstein Sellers & Toll PLLC, a nationally recognized leader in investor protection, announces that investors who purchased shares of Zenas BioPharma, Inc. (NASDAQ: ZBIO) in the company’s September 2024 initial public offering may seek to lead a federal securities class action. The deadline to move for appointment as lead plaintiff is June 16, 2025. [Click here for information about joining the class action] If you’d like to discuss this matter or your righ ...

NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zenas BioPharma, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons who purchased or otherwise acquired Zenas BioPharma securities pursuant and/or traceable to the registration state ...

Core Viewpoint - A class action securities lawsuit has been filed against Zenas BioPharma, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's September 2024 initial public offering [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors adversely affected by alleged securities fraud related to Zenas BioPharma [2]. - The complaint alleges that Zenas BioPharma materially overstated its ability to fund operations using existing cash and expected net proceeds from the IPO, leading to false and misleading public statements [3]. Group 2: Investor Information - Investors who suffered losses in Zenas BioPharma have until June 16, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securing compensation for shareholders and is recognized as one of the top securities litigation firms in the United States [5].

WASHINGTON, D.C., May 01, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (NASDAQ: ZBIO) entered the public markets in September 2024 with a $17 per share debut and bold projections. But within weeks, investors were facing a much different picture—one that has now led to a securities class action lawsuit and an upcoming court deadline. Cohen Milstein Sellers & Toll PLLC, one of the nation’s top securities law firms, is calling on investors who purchased shares during the IPO to consider joining and seeking a ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Zenas BioPharma, Inc. regarding a class action lawsuit due to alleged misleading statements made by the company during its initial public offering in September 2024 [1][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of individuals who purchased Zenas BioPharma securities during the specified class period related to the company's IPO [3]. - Allegations include that Zenas BioPharma overstated its ability to fund operations with existing cash and expected IPO proceeds, leading to materially false and misleading public statements [4]. - The deadline for shareholders to register for the class action is June 16, 2025, and there is no cost to participate [5]. Group 2: Firm's Commitment - The Gross Law Firm aims to protect investors' rights against deceit and fraud, emphasizing the importance of responsible business practices [6]. - The firm seeks recovery for investors who suffered losses due to misleading statements that inflated the company's stock price [6].

NEW YORK, May 1, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO).Shareholders who purchased shares of ZBIO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/zenas-biopharma-inc-loss-submission-form/?id=146175&from=4CLASS PERIOD: This lawsuit ...

Core Viewpoint - A class action has been filed against Zenas BioPharma, Inc. for allegedly misleading investors during its IPO, particularly regarding the company's financial sustainability and operational funding timeline [1][2]. Allegations - The complaint states that Zenas BioPharma materially overstated its ability to fund operations, claiming it could do so for twenty-four months instead of the actual twelve months as disclosed in its Form 10-Q filed on November 12, 2024 [2]. - Following the revelation of these omitted material facts, Zenas BioPharma's stock price has significantly declined, closing at $8.72 on April 15, 2025, which is 48.7% lower than its IPO price [2]. Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their papers by June 16, 2025, and can remain absent class members if they choose not to participate [3]. Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is won [4].

Core Viewpoint - A class action securities lawsuit has been filed against Zenas BioPharma, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's September 2024 initial public offering [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors adversely affected by the alleged fraud [2]. - The complaint claims that Zenas BioPharma overstated its ability to fund operations with existing cash and expected IPO proceeds, leading to materially false and misleading public statements [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Zenas BioPharma have until June 16, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [5]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [5].